Title: What is the case fatality rate after cyclopeptide-mushroom poisoning.<br/>Author: Hong Kim<br/><a href='http://umem.org/profiles/faculty/526/'>[Click to email author]</a><hr/><p>
</p>
<p>
Cyclopeptides (Amatoxin)-containing mushroom poisoning results in delayed development of gastrointestinal symptoms that may progress to liver failure. There is no established antidotal treatment for cyclopeptide-induced hepatic failure; silibinin is currently under investigation. </p>
<p>
There is a wide range of case fatality reported from cyclopeptides-containing mushroom poisoning: 4.8% to 47%.</p>
<p>
National Poison Data System was reviewed from 1/1/2008 to 12/31/2018 for all suspected cyclopeptides containing mushroom poisoning. Out of 8953 suspected cases, 148 cases were included in the study.</p>
<p>
Results:</p>
<ul>
<li>
Northeast 50 (33.8%)</li>
<li>
West cost: 46 (31.1%)</li>
<li>
Southeast: 22 (14.9%)</li>
<li>
Midwest: 24 (16.2%)</li>
<li>
Southcentral: 6 (4.1%)</li>
</ul>
<p>
Therapy:</p>
<ul>
<li>
NAC: 101 (68.2%)</li>
<li>
Penicillin: 42 (28.4%)</li>
<li>
Multi-dose activated charcoal: 35 (23.6%)</li>
<li>
Silibinin IV: 30 (20.3%)</li>
<li>
Silibinin PO: 12 (8.1%)</li>
</ul>
<p>
Case fatality</p>
<ul>
<li>
Overall: 8.8%</li>
<li>
Treated with silibinin/silymarin: 9.5%</li>
<li>
Not treated with silibinin/silymarin: 8.5%</li>
</ul>
<p>
Conclusion:</p>
<ul>
<li>
Overall fatality of cyclopeptide mushroom poisoning was 8.8%</li>
<li>
In this retrospective study, silibinin treatment did not appear to decrease the fatality rate.</li>
</ul>
<fieldset><legend>References</legend>
<p>
De Olan J et al. Current fatality rate of suspected cyclopeptide muschroom poisoning in the United States. Clin Toxicol (Phila.) 2020. DOI: 10.1080/15563650.2020.1747624</p>
</fieldset>